Search Results

You are looking at 1 - 10 of 67 items for :

  • "Epstein-Barr virus" x
  • All content x
Clear All

Macsween, K. F., Crawford, D. H.: Epstein-Barr virus-recent advances. Lancet Infect. Dis. 3 , 131–140 (2003). Crawford D. H. Epstein-Barr

Restricted access

Epstein-Barr virus specified small RNA molecules. Nucleic Acids Res 10 , 3407–3425 (1982). Arrand J. R. In vitro transcription of two Epstein-Barr virus specified small RNA molecules

Open access
Hematológia–Transzfuziológia
Authors: Livia Vida, Gábor Ottóffy, Barnabás Rózsai, József Stankovics, Beáta Tóth, Zoltán Nyúl, and Béla Kajtár

evidence for Epstein–Barr virus infection. Br J Haematol. 2000; 108: 377–382. 5 Swerdlow SH, Campo E, Harris NL, et al. (ed). WHO Classification of Tumours of Haematopoietic and

Restricted access

2008 Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases Autoimmunity 41 298 – 328

Restricted access

The EBV carrier state is almost general in men. The virus induces B lymphocyte proliferation in vitro, but this is counteracted in vivo by the immune response. Therefore, EBV-induced malignancies occur only when the immune response is impaired, e.g. in transplant recipients. The versatility of the viral gene expression strategy secures the consistent maintainance of the virus in healthy individuals. The viral proteins required for transformation render the cell immunogenic. Expression of the transforming genes leads to rejection, but these genes are not required for the maintenance of the viral genome. EBV is an important contributor for malignant transformation, even when it does not directly induce cell proliferation. Several mechanisms have been unravelled in EBV-associated tumors whereby the virus may modify the cellular phenotype and may influence the interaction of tumor cells with their microenvironment. The virus carrier state can lead to the evasion of apoptosis and can intensify the response to growth promoting signals, too.

Restricted access
Orvosi Hetilap
Authors: Péter Rajnics, László Krenács, András Kenéz, Zoltán Járay, Enikő Bagdi, and Judit Demeter

natural killer-cell line established from natural killer cell lymphoma/leukemia associated with Epstein–Barr virus infection. Blood, 1998, 92 , 1374–1383. Mori M. Characterisation

Restricted access
Orvosi Hetilap
Authors: Anita Stréhn, László Szőnyi, Gergely Kriván, Lajos Kovács, György Reusz, Attila Szabó, Imre Rényi, Gábor Kovács, and Antal Dezsőfi

-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am. J. Respir. Crit. Care Med., 2008, 178 (10), 1060–1065. Sato, T., Fujieda, M., Tanaka, E., et al.: Monitoring of Epstein-Barr virus load and

Open access

. Gastroenterol., 2013, 62 (1), 3–26. Murphy, G., Pfeiffer, R., Camargo, C., et al.: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location

Restricted access
Acta Microbiologica et Immunologica Hungarica
Authors: Elena Nikolaevna Filatova, Nikolay Aleksandrovich Sakharnov, Dmitry Igorevich Knyazev, and Oleg Vladimirovich Utkin

Introduction Epstein-Barr virus (EBV, Human gammaherpesvirus 4 ) is a ubiquitous human oncogenic virus that persists in over 90% of the world’s population. It is known that EBV makes a significant contribution to several human

Restricted access
Physiology International
Authors: K. Kalantar, Z. Farzaneh, M. Eshkevar Vakili, M.H. Karimi, M. Asadi, S. Khosropanah, and M. Doroudchi

reported which include both microbial and self-antigens. Among bacterial and viral pathogens, Chlamydia pneumoniae, Helicobacter pylori , Porphyromonas gingivalis , Cytomegalovirus (CMV), Epstein-barr virus (EBV) and influenza (Flu) virus [ 12 ] are

Restricted access